Altimmune, Inc. company information, Employees & Contact Information

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide Yahoo Finance

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer GlobeNewswire

Altimmune, Inc. to Host Investor Webcast Presenting Topline Data from IMPACT Phase 2b Trial of Pemvidutide for MASH Treatment Nasdaq

Altimmune Appoints Jerry Durso as Chairman as Company Advances to Phase 3 Development of Pemvidutide Quiver Quantitative

Late-Stage Biotech Altimmune Announces Triple Conference Presence: Wells Fargo, HC Wainwright, Morgan Stanley Stock Titan

Altimmune Board of Directors Appoints Jerry Durso as Chairman Yahoo Finance

Altimmune, Inc. Appoints Linda M. Richardson as Chief Commercial Officer Quiver Quantitative

Late-Stage Biotech Altimmune to Showcase Pipeline at Major Cardiometabolic and Liver Disease Forums Stock Titan

Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 Yahoo Finance

Altimmune, Inc. to Announce Q1 2025 Financial Results on May 13, 2025 Quiver Quantitative

Altimmune Announces Second Quarter 2025 Financial Results and Business Update Yahoo Finance

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) Yahoo Finance

Altimmune Announces First Quarter 2025 Financial Results and Business Update Yahoo Finance

Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions Yahoo Finance

Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital Yahoo Finance

Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) Yahoo Finance

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) Yahoo Finance

Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH Yahoo Finance

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025 Yahoo Finance

30-Year Pharma Veteran Linda Richardson Joins Altimmune as CCO to Lead Pemvidutide Commercialization Stock Titan

Strategic Shift: Altimmune Taps Commercial Expert Jerry Durso as Chairman Before Crucial MASH Drug Phase 3 Stock Titan

28M Patient Market: Altimmune's Novel Drug Gets FDA Fast Track for Alcohol Use Disorder Treatment Gap Stock Titan

Clinical-Stage Biotech Altimmune Sets Q2 2025 Earnings Date - Key Details for Investors Stock Titan

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 Yahoo Finance

Altimmune Announces First Quarter 2025 Financial Results and Business Update Stock Titan

Altimmune Sets Double Conference Appearance: HC Wainwright and Jefferies Healthcare Events Coming Up Stock Titan

Breakthrough GLP-1/Glucagon Drug Pemvidutide Reveals Multiple Cardiometabolic Benefits in New Clinical Data Stock Titan

Breakthrough ALD Drug Enters Phase 2 Trial: Targets 6M Patient Market with No Approved Treatments Stock Titan

Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders Yahoo Finance

Altimmune, Inc. Added to Nasdaq Biotechnology Index Effective December 23, 2024 Quiver Quantitative

Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 The Manila Times

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity Yahoo Finance

Altimmune Appoints Greg Weaver as CFO citybiz

Altimmune's Pemvidutide Shows 68.5% Liver Fat Reduction in Phase 1b Trial Results Stock Titan

Altimmune Advances Obesity Drug: FDA Greenlights Major Phase 3 Program Design Stock Titan

Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt citybiz

Altimmune Appoints Richard Eisenstadt as Chief Financial Officer citybiz

Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial GlobeNewswire

Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial GlobeNewswire

Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine GlobeNewswire